Next Generation Health Technology Assessment to support patient-centred, societally oriented, real-time decision-making on access and reimbursement for health technologies throughout Europe
Akronym
HTx
Bidragets beskrivning
HTx will create a framework for next generation Health Technology Assessment (HTA) that supports patient-centred, societally oriented, and real-time decision-making for integrated healthcare throughout Europe. HTx will focus on therapeutic areas with high unmet need for which HTA information has to be provided on complex and personalised combinations of health technologies.
Based on a select number of relevant case studies, HTx will enhance methods for integrating evidence from RCTs and real-world data (RWD). HTx will also augment statistical and econometric methods for generating robust estimates of effectiveness and cost-effectiveness in order to support relevant HTA decision-making for these complex and personalised combinations of health technologies.
HTx will also contribute to improving methods to support personalised treatment advice fitted for sharing with patients and their physicians. This includes the development of statistical and econometric approaches and artificial intelligence/machine learning methods for forecasting treatment effects in specific groups of patients.
Simultaneously, in close collaboration with the European Network for HTA (EUnetHTA), HTx will improve synergies between regulatory agencies, HTA bodies and clinical guideline developers. This will include the translation of HTx methods into already existing European guidelines, most prominently those developed by EUnetHTA. HTx will also support initial efforts to discuss reimbursement and funding models that facilitate controlled access to and the pricing of these complex health technologies.
Finally, we will evaluate the transferability of HTx results into all EU Member Countries especially in Central and Eastern European (CEE) Countries and promote the dissemination of HTx results to the different European stakeholders with a special focus on the patient community.
Visa merStartår
2019
Slutår
2024
Beviljade finansiering
SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG (HU)
679 162.5 €
Participant
TANDVARDS-OCH LAKEMEDELSFORMANSVERKET (SE)
301 851.88 €
Participant
ZORGINSTITUUT NEDERLAND (NL)
484 450 €
Participant
EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION (FR)
625 907.5 €
Participant
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (UK)
839 398.13 €
Participant
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL (ES)
726 687.5 €
Participant
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL (BE)
402 250 €
Participant
MEDICAL UNIVERSITY SOFIA (BG)
313 687.5 €
Participant
ACADEMISCH ZIEKENHUIS GRONINGEN (NL)
137 500 €
Third party
UNIVERSITAIR MEDISCH CENTRUM UTRECHT (NL)
322 500 €
Third party
UNIVERSIDAD POLITECNICA DE MADRID (ES)
382 100 €
Participant
UNIVERSITEIT MAASTRICHT (NL)
384 855 €
Participant
UNIVERSITAET BERN (CH)
749 062.5 €
Participant
UNIVERSITY OF YORK (UK)
984 602.5 €
Participant
UNIVERSITEIT UTRECHT (NL)
1 352 134.99 €
Coordinator
KOBENHAVNS UNIVERSITET (DK)
228 125 €
Participant
Beviljat belopp
9 640 775 €
Finansiär
Europeiska unionen
Typ av finansiering
Research and Innovation action
Ramprogram
Horizon 2020 Framework Programme
Utlysning
Programdel
Health (5290 Health care provision and integrated care (5309 )
Tema
HTA research to support evidence-based healthcare (SC1-BHC-26-2018Utlysnings ID
H2020-SC1-2018-Single-Stage-RTD Övriga uppgifter
Finansieringsbeslutets nummer
825162
Identifierade teman
health care